Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Wainwright

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 5, 2026
Is the gut a reservoir of non-tuberculous mycobacteria in people with cystic fibrosis?Jennifer Hudson, Nicole Taylor, Michael J Coffey, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical TrialClaire Wainwright, Susanna A McColley, Paul McNally, et al.
The Lancet. Respiratory Medicine|June 6, 2022
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trialStephen M Stick, Alexia Foti, Robert S Ware, et al.
American Journal of Respiratory and Critical Care Medicine|June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension StudyClaire Wainwright, Susanna A McColley, Paul McNally, et al.
Vaccine|November 18, 2022
Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national studyNusrat Homaira, Roxanne Strachan, Helen Quinn, et al.
Annals of the American Thoracic Society|March 8, 2023
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical InterpretationsRhonda Szczesniak, Eleni-Rosalina Andrinopoulou, Weiji Su, et al.
Cancer Medicine|June 2, 2023
Development of cancer surveillance guidelines in ataxia telangiectasia: A Delphi-based consensus survey of international expertsRenata Neves, Blanca De Dios Perez, Rafal Panek, et al.
BMJ Open|September 21, 2025
Finding the optimal regimen for <i>Mycobacteroides abscessus</i> treatment (FOR<i>Ma</i>T) in people with <i>Mycobacteroides abscessus</i> pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trialTiffany Jong, Timothy Baird, Helen Louise Barr, et al.
JAMA|September 10, 2009
Genetic modifiers of liver disease in cystic fibrosisJaclyn R Bartlett, Kenneth J Friedman, Simon C Ling, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2024
Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issuesPierre-Régis Burgel, Kevin W Southern, Charlotte Addy, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 5, 2026
Is the gut a reservoir of non-tuberculous mycobacteria in people with cystic fibrosis?Jennifer Hudson, Nicole Taylor, Michael J Coffey, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical TrialClaire Wainwright, Susanna A McColley, Paul McNally, et al.
The Lancet. Respiratory Medicine|June 6, 2022
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trialStephen M Stick, Alexia Foti, Robert S Ware, et al.
American Journal of Respiratory and Critical Care Medicine|June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension StudyClaire Wainwright, Susanna A McColley, Paul McNally, et al.
Vaccine|November 18, 2022
Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national studyNusrat Homaira, Roxanne Strachan, Helen Quinn, et al.
Annals of the American Thoracic Society|March 8, 2023
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical InterpretationsRhonda Szczesniak, Eleni-Rosalina Andrinopoulou, Weiji Su, et al.
Cancer Medicine|June 2, 2023
Development of cancer surveillance guidelines in ataxia telangiectasia: A Delphi-based consensus survey of international expertsRenata Neves, Blanca De Dios Perez, Rafal Panek, et al.
BMJ Open|September 21, 2025
Finding the optimal regimen for <i>Mycobacteroides abscessus</i> treatment (FOR<i>Ma</i>T) in people with <i>Mycobacteroides abscessus</i> pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trialTiffany Jong, Timothy Baird, Helen Louise Barr, et al.
JAMA|September 10, 2009
Genetic modifiers of liver disease in cystic fibrosisJaclyn R Bartlett, Kenneth J Friedman, Simon C Ling, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2024
Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issuesPierre-Régis Burgel, Kevin W Southern, Charlotte Addy, et al.
Pageof 5